Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Braintree Laboratories |
---|---|
Information provided by: | Braintree Laboratories |
ClinicalTrials.gov Identifier: | NCT00153140 |
The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.
Condition | Intervention | Phase |
---|---|---|
Constipation |
Drug: polyethyleneglycol3350 |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | Polyethyleneglycol3350 Vs Tegaserod in Treatment of Patients With Chronic Constipation |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Patients currently taking, or planning to take any of the following medications that are known to effect bowel habits:
Principal Investigator: | Jorge Herrera, MD | University of South Alabama |
Study ID Numbers: | 851-ZCC |
Study First Received: | September 7, 2005 |
Last Updated: | September 7, 2005 |
ClinicalTrials.gov Identifier: | NCT00153140 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Signs and Symptoms, Digestive Constipation Tegaserod |
Signs and Symptoms Signs and Symptoms, Digestive Constipation |